Regulatoriskt pressmeddelande

BBS-Bioactive Bone Substitutes Plc Apply for Delisting from Nasdaq First North

BBS-Bioactive Bone Substitutes Plc | Company Release | March 05, 2025 at 14:30:00 EET

The Board of Directors of BBS-Bioactive Bone Substitutes Plc ("BBS" or the "Company") resolved at its meeting on February 12, 2025, to file for bankruptcy. Subsequently, the Oulu District Court declared the Company bankrupt on February 17, 2025, at 1:00 PM (Decision Number: 25/4037, Case K 25/3957).

In light of this development, the Company has applied to delist its shares from the Nasdaq First North Growth Market, following applicable regulations. Once the company receives confirmation from Nasdaq First North, it will announce the final trading date for BBS shares in a separate press release.

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi